Products from TargetMol
TargetMol, based in Boston, Massachusetts, was founded in 2015 and is a drug screening expert in the life science community. The company offers diverse compound libraries, including FDA-approved libraries, and covers a broad spectrum of small molecule compounds such as inhibitors and agonists as well as recombinant proteins and natural products. TargetMol's products are used by researchers worldwide in areas such as cancer research, neurobiology, inflammation, immunology and metabolism.
More information at: www.targetmol.com
No results were found for the filter!
HCV-IN-43
Item number: TGM-T79625-100mg
Description: HCV-IN-43 (compound 2), an HCV NS5B protein inhibitor, efficiently inhibits HCV virus replication and is utilized in the study of HCV infection [1]. Target: Others
| CAS | 1850311-28-2 |
| MW: | 511.57 D |
From 1,867.00€
*
HCV-IN-44
Item number: TGM-T79626-100mg
Description: HCV-IN-44 (compound 28) is an inhibitor of the HCV NS5B protein, effective in suppressing HCV virus replication and useful for researching HCV infection [1]. Target: Others
| CAS | 1850311-55-5 |
| MW: | 487.54 D |
From 1,867.00€
*
Tubulin polymerization-IN-46
Item number: TGM-T79629-50mg
Description: Tubulin polymerization-IN-46 (compound 9q) is a microtubule/tubulin inhibitor that obstructs tubulin polymerization, triggers apoptosis, and arrests MCF-7 breast cancer cells in the G2/M phase, demonstrating potent anti-proliferative activity with an IC50 of 10 nM [1]. Target: Others
| MW: | 399.44 D |
Please request pricing for this article.
CDK9-IN-25
Item number: TGM-T79630-50mg
Description: CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 µM. It also exhibits affinity for the main protease of COVID-19 and demonstrates antiviral activity against human coronavirus 229E, with an IC50 of 63.28 µM [1]. Target: Virus Protease
| MW: | 285.32 D |
Please request pricing for this article.
CDK9-IN-26
Item number: TGM-T79631-50mg
Description: CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 µM.[1]. Target: CDK
| MW: | 306.32 D |
Please request pricing for this article.
Antileishmanial agent-21
Item number: TGM-T79632-50mg
Description: Antileishmanial agent-21 (compound 4e) functions as an inhibitor of Leishmania pteridine reductase 1 (Lm-PTR1), employing an anti-folate mechanism. Its antileishmanial effects can be negated by folic acid and leucovorin. Additionally, it demonstrates inhibitory activity against the chloroquine-resistant...
| MW: | 344.36 D |
Please request pricing for this article.
Antileishmanial agent-22
Item number: TGM-T79633-50mg
Description: Antileishmanial agent-22 (compound 15b) acts as an antiparasitic and antibacterial agent, demonstrating activity against Leishmania (IC50 = 0.408 µM), malaria, and tuberculosis. It functions via an antifolate mechanism, inhibiting folic and folinic acids with 88% and 94% efficacy at 100 µM. The compound...
| MW: | 549.45 D |
Please request pricing for this article.
SIRT5 inhibitor 8
Item number: TGM-T78856-50mg
Description: SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor of sirtuin SIRT5 with an IC50 of 5.38 µM and exhibits anticancer potential [1]. Target: Sirtuin
| MW: | 501 D |
From 1,070.00€
*
SIRT5 inhibitor 9
Item number: TGM-T78857-50mg
Description: SIRT5 inhibitor 9 (compound 14), with an IC50 of 4.07 µM, is a competitive inhibitor of the sirtuin SIRT5, exhibiting potential anticancer properties [1]. Target: Sirtuin
| MW: | 561.06 D |
From 1,070.00€
*
MAO-B-IN-23
Item number: TGM-T78859-100mg
Description: MAO-B-IN-23, also known as Compound 11f, is a reversible and competitive monoamine oxidase B (MAO-B) inhibitor with an IC50 value of 1.44 µM and a Ki of 0.51 µM [1]. Target: Monoamine Oxidase
| CAS | 2107978-22-1 |
| MW: | 356.26 D |
From 1,440.00€
*
MAO-B-IN-24
Item number: TGM-T78860-50mg
Description: MAO-B-IN-24 (compound 11h) is a selective, reversible, competitive inhibitor of MAO-B with an IC50 value of 1.60 µM and an IC50 of 22.42 µM for MAO-A. At 10 µM concentration, it reduces AChE and BChE activities to 54.58% and 88.43%, respectively [1]. Target: Monoamine Oxidase
| MW: | 302.37 D |
Please request pricing for this article.
HDAC8-IN-5
Item number: TGM-T78861-50mg
Description: HDAC8-IN-5 (Compound 6a), with an inhibitory concentration (IC50) of 28 nM, is a potent HDAC8 inhibitor suitable for cancer research [1]. Target: HDAC
| MW: | 277.23 D |
Please request pricing for this article.